Alternaria Mold Allergy: Thunderstorm Asthma, Alt a 1, and Immunotherapy

Yes — and Alternaria is the mold most strongly linked to severe and fatal asthma. A landmark 1991 study in the New England Journal of Medicine found that 10 of 11 patients who experienced asthma-related respiratory arrest had positive Alternaria skin tests, yielding an adjusted odds ratio of 189.5. This is one of the highest asthma risk magnitudes recorded in the allergy literature. Beyond severe attacks, Alternaria sensitization is also associated with difficult-to-control asthma and a recognized clinical entity called severe asthma with fungal sensitization (SAFS). Any patient with asthma that worsens in summer and fall — especially after thunderstorms — should discuss Alternaria skin testing with a board-certified allergist.

Thunderstorm asthma occurs when storm outflows break apart large Alternaria spores (normally 20–60 µm) into ultra-fine fragments small enough to bypass nasal filtration and reach the lower airways directly. Cold storm downdrafts concentrate these particles at ground level, dramatically increasing the effective inhaled allergen dose in sensitized individuals. The most severe documented event was the Melbourne 2016 thunderstorm, which caused 3,365 excess emergency department visits, 476 asthma admissions, and 10 deaths over a single night. A 2000 UK study found that Alternaria-sensitized patients had a 9.31 times higher risk of thunderstorm asthma compared to non-sensitized individuals. Sensitized patients should close windows and stay indoors when severe thunderstorms are forecast during summer and early fall.

Alt a 1 is the dominant allergen protein of Alternaria alternata — a unique 29–30 kDa β-barrel homodimer with no known biological function and no homologues outside fungi. Between 80–100% of Alternaria-sensitized patients have IgE antibodies against Alt a 1. This high prevalence makes it an ideal diagnostic marker. The recombinant Alt a 1 component test (ImmunoCAP m229) distinguishes patients with genuine primary Alternaria sensitization from those with cross-reactive antibodies against pan-fungal proteins like enolase. This distinction matters for immunotherapy: patients who are Alt a 1-positive have the clearest indication for Alternaria-specific SCIT or SLIT, while those positive only via enolase cross-reactivity may actually have primary Cladosporium sensitization.

Yes — and Alternaria is uniquely positioned as the ONLY mold species with robust controlled trial evidence for allergen immunotherapy. Subcutaneous immunotherapy (allergy shots) with Alternaria extract has been validated in multiple DBPC-RCTs. Kuna et al. (JACI 2011) showed 63.5% reduction in combined symptom-medication scores after 3 years of SCIT. Tabar et al. (JACI 2019) demonstrated efficacy with purified native Alt a 1 after just one year. Sublingual immunotherapy (SLIT drops) also has trial data for Alternaria — Pozzan and Milani found 97% clinical improvement at 3 years with SLIT versus 27% in controls. Treatment typically runs 3–5 years for sustained benefit. US extracts are currently non-standardized, while European preparations offer better consistency.

Alternaria season peaks from July through September in most of the United States, tapering as temperatures drop in October. The mold thrives on dying vegetation, harvested crops, and compost under warm, moderately dry conditions. Outdoor spore counts can reach 7,500 spores/m³ during peak periods — and because the symptom threshold for sensitized individuals is as low as 100 spores/m³, even moderate count days can trigger reactions. Spore release peaks during warm, dry afternoons and after agricultural activities. Counts approach zero in winter. In the southern US and during unusually warm autumns, the season may extend into October or November. Monitoring AAAAI's National Allergy Bureau mold count reports helps sensitized patients plan daily outdoor activities.

Yes — although Alternaria is predominantly an outdoor mold, it can colonize indoor damp surfaces including windowsills, bathrooms, basements, and carpets. NHANES data found Alternaria in 25.5% of US bedroom dust samples. Indoor growth typically requires relative humidity above 84–89% on an ongoing basis. Common indoor sites include areas around windows with condensation, bathrooms without adequate ventilation, and basements with water seepage. To prevent indoor growth, maintain indoor humidity between 30–50%, fix water leaks within 24–48 hours, ensure bathroom exhaust fans function properly, and clean windowsills regularly. A professional inspector or environmental assessment is warranted if significant indoor mold growth is suspected.

Both are outdoor dematiaceous molds that peak in summer and early fall, but they differ critically in potency, allergen characteristics, and clinical risk. Cladosporium is the most abundant outdoor mold globally — with counts reaching 50,000 spores/m³ — yet requires approximately 3,000 spores/m³ to trigger symptoms. Alternaria counts peak lower (7,500 spores/m³) but the symptom threshold is just 100 spores/m³ — making Alternaria 30 times more potent per spore. Alternaria carries the overwhelming association with severe and fatal asthma (OR 189.5 for respiratory arrest); Cladosporium does not. Immunotherapy for Alternaria has robust DBPC-RCT evidence; for Cladosporium it has only one very early trial with noted safety concerns. Patients sensitized to both have an OR of 63.97 for thunderstorm asthma — a multiplicative risk amplification.

Yes, and Alternaria-sensitized children face particularly serious risks. Children with asthma who are sensitized to Alternaria are at elevated risk for severe, near-fatal asthma events — especially during thunderstorms in summer and fall. Sensitization can develop in early childhood, with studies documenting Alternaria-specific IgE in children as young as 2–3 years in high-exposure environments. Symptoms in children often begin with recurrent nighttime cough during summer, exercise-induced breathing difficulties in late summer, and worsening asthma after thunderstorms. A board-certified pediatric allergist can perform skin prick testing and, if appropriate, recommend allergen immunotherapy — which has been validated in pediatric populations in the Kuna et al. JACI 2011 trial.

The bedroom is the highest-priority location for a HEPA air purifier in patients with Alternaria allergy, given the 6–8 hours of overnight exposure. A true HEPA filter (not 'HEPA-type') captures ≥99.97% of particles ≥0.3 µm — well within the range of Alternaria spores and their respirable fragments. Place the unit away from walls, run it continuously at medium speed during allergy season (July–October), and replace filters every 6–12 months. During peak mold count days, keeping the bedroom door closed with the purifier running maintains a lower-spore refuge for sleeping. For patients with severe asthma, HEPA filtration in living areas and home offices may also be warranted. Portable purifiers designed for rooms 200–400 sq ft are most effective when matched to room size.

Without appropriate management, Alternaria allergy can progress in severity over time through two main mechanisms. First, repeated episodes of allergic airway inflammation cause cumulative airway remodeling — structural changes including subepithelial fibrosis and smooth muscle hypertrophy that can lead to fixed (non-reversible) airflow obstruction. Second, untreated sensitization may expand to include additional allergens through a process called epitope spreading, broadening the allergic response. Patients with untreated Alternaria-driven asthma who experience repeated severe attacks — including those triggered by thunderstorms — face increasing risk of permanent lung function decline. Early intervention with appropriate medication and, when indicated, allergen immunotherapy can interrupt this progression. A board-certified allergist can assess current disease severity and recommend whether immunotherapy is appropriate for your specific situation.